Why has the study of relapse phenotype (system involvement, severity and temporal placement within the clinical course of multiple sclerosis (MS)) been so delayed? Several studies have found predictive value in phenotyping initial bouts of MS by system involvement, and severity, 1, 2 but what of later relapses? Challenges exist in performing studies involving longterm natural history cohorts, the greatest perhaps being the lack of available detailed information on each relapse in each patient followed. Therapeutic trial data, although precise in terms of mode and duration of relapse symptoms, are generally limited to only a few years. Although attacks occurring at any point in the relapsing phase can indeed result in worsening of disability, 3 and can be measured relatively easily, it remains unclear how to quantitate the burden of disease over many years due to relapse versus other types of worsening (gradual, age related). Limitations exist concerning the lack of accepted methodologies for measurement of medium and long-term outcomes.
In spite of these and other challenges, a refinement of our understanding of different phenotypes of MS relapses is emerging. For example, placing a specifically characterized MS relapse within the overall clinical course of MS may now have quantified relevance based on at least one recent study (a motor system relapse with poor recovery at any point in the course of relapsing MS may herald secondary progressive MS). 4 Another recent study adds to our understanding of MS relapses, by demonstrating for the first time an association between the occurrence of relapses and a worse prognosis even after the onset of a progressive course. 5 These recent studies express some disagreement with earlier studies concerning the importance of the temporal placement of various types of relapses within the course of MS, although there is general agreement that the mode and severity of initial attacks can at least modestly affect long-term outcomes. Earlier studies have suggested that relapses in general play almost no role in long-term outcomes, as their predictive value is largely or completely lost after the first 2-5 years. 6, 7 By way of likely explanation for the difference in these findings and those of more recent work, the mode and severity of attacks were not accounted for in earlier versus recent studies. What has only recently been calculated is the significance of a motor attack (versus sensory), with incomplete recovery (versus complete), in later MS (versus very early).
Perhaps partly due to the characteristics of our most used disability scale, worsening MS tends to involve motor systems more so than sensory systems even after initial attacks. 8, 9 It can thus be inferred that relapses involving the motor system will more likely continue to contribute to long-term outcomes even after early relapses, but analysis of long-term datasets was lacking in these studies. A few other recent studies that do involve long-term data show that both motor system relapses and relapses with residua in later MS are associated with a more progressive picture and particularly rapid progression of disability. 4, 10 It is worth again emphasizing a particular recent study, which showed that a motor system attack with incomplete recovery occurring at any point in the disease modifies the risk of transition to secondary progressive MS (thus exposing predictive value by placing a specific relapse phenotype within a specific clinical course). 4 Similarly, a disease course with at least one year of slow worsening combined with at least one year with confirmed sequelae from relapse confers a higher long-term risk of poor outcome than 
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a pattern of worsening free from relapse sequelae. 10 Although the importance of relapses appears to diminish with each 5 year epoch of relapsing MS, the number of patients affected by stepwise loss of neurological function, and a mixed picture of stepwise and gradual loss of function appears not to be trivially small. 7, 10 Elucidation of the importance of relapses needs to be reconciled with the appearance of a slow and inexorable pattern of secondary progression in most disabled patients. 6 It is not clear from our present therapeutic trials how treatments alter or reduce the appearance of this phase. Can elimination of relapses lead to elimination of secondary progressive MS in some or most patients? Although the onset of advanced disability is rarely the effect of a single relapse, 11 worsening of disease to a new level of disability occurs with a large portion of relapses. 3 The cumulative effect of relapses over time in seminal natural history studies has only been modeled in terms of relapse frequency. The more recent studies reviewed here go beyond merely counting frequency and suggest that certain relapse types are associated with a more progressive and disabling picture, and can be used in predictive models of MS progression. At least until precise biomarkers for MS prognosis are developed, we should continue in the endeavor of relapse phenotyping. It is likely that the identification of meaningful clinical phenotypes will be needed to inform researchers of the possible application of genotypic discoveries of the future.
Important to the ongoing study of relapse phenotype, we now have a widely recommended new lexicon to describe the clinical course of MS, placing increased emphasis on relapse activity and focusing on relapse recovery. 12 The creation of accepted terminology to describe the extreme variability of the course of MS, including periods of remission appearing to be induced by therapeutics, will be central to our methodologies as we explore increasingly complex datasets. For example, we might now agree to describe a patient with a history of yearly stepwise decline due to relapse sequelae as 'stable' in subsequent years if free from relapse or worsening. The timing of stability relative to changes in therapeutics remains of obvious clinical interest (dare we contemplate it, a 'drug induced remission'?). Perhaps skepticism about the long-term utility of our growing armamentarium of therapeutic agents has stunted the study of relapse phenotype in MS, but we are now seeing datasets from clinical trials subjected to post hoc study of relapse severity yielding clues to mechanisms of action. 13, 14 Perhaps we can soon join our colleagues in other treatment areas of autoimmune illness who have pressed forward with a longer history of tangible gains concerning remissions. 15 More needs to be done to verify and clarify the importance of the findings of the recent studies outlined here, all of which point to a quantifiable effect of specifically characterized relapses at various disease time points. Perhaps these studies will help conclude the awkward debate among MS specialists, 'do relapses matter?'. 16 At least a modest effect, and quite possibly something more, is suggested by the accumulation of these studies of specifically phenotyped relapses. Ultimately, treating physicians will apply these findings in conjunction with magnetic resonance imaging (MRI) data and other predictive information, which at this time remains limited. Although some studies indicate MRI measures may be more predictive than clinical measures for short-term outcome in patients on interferon beta therapy, 17 extension of this work into long-term outcomes and across therapeutic schemes other than interferon beta therapy is still awaited.
Concerning the null hypothesis that relapses are only minimally informative of future events, researchers should apply the dictum that absence of proof is not proof of absence. A tradition of reporting a minimal impact of relapses should now be viewed as misleading. The absence of evidence in an earlier era of MS studies relates to inadequate modeling of the longterm effects of relapses. Moving forward with new models incorporating detailed relapse phenotyping holds much promise. If we can agree that properly phenotyped relapses are important for more than just a few patients, we can provide a more clearly defined target for our therapies.
